Innate Pharma
Clinical-stage biotech developing immunotherapies for cancer using the innate immune system.
IPH | PA
Overview
Corporate Details
- ISIN(s):
- FR0010331421 (+1 more)
- LEI:
- 9695002Y8420ZB8HJE29
- Country:
- France
- Address:
- 117 AVENUE DE LUMINY, 13009 MARSEILLE
- Website:
- http://www.innate-pharma.com/
- Sector:
- Manufacturing
Description
Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-11-17 07:00 |
Innate Pharma présente ses résultats financiers et l'avancée de son portefeuill…
|
French | 424.6 KB | ||
| 2020-11-17 07:00 |
Innate Pharma reports third quarter 2020 financial results and business update
|
English | 421.2 KB | ||
| 2020-11-13 07:00 |
INNATE PHARMA REÇOIT LE STATUT « PRIME » DE L’AGENCE EUROPÉENNE DU MÉDICAMENT P…
|
French | 90.6 KB | ||
| 2020-11-13 07:00 |
INNATE PHARMA RECEIVES PRIME DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR…
|
English | 139.9 KB | ||
| 2020-11-12 07:00 |
Participation d'Innate Pharma à de prochains rendez-vous investisseurs
|
French | 152.4 KB | ||
| 2020-11-12 07:00 |
Innate Pharma to participate in upcoming investor conferences
|
English | 146.6 KB | ||
| 2020-10-26 13:57 |
Franchissement de seuils et déclaration d'intention
|
French | 216.1 KB | ||
| 2020-10-23 07:00 |
First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment…
|
English | 234.1 KB | ||
| 2020-10-23 07:00 |
L'inclusion du premier patient dans l'essai clinique de Phase 3 avec monalizuma…
|
French | 233.5 KB | ||
| 2020-10-13 07:00 |
NOUVEAU NOMBRE D’ACTIONS ET DE DROITS DE VOTE D’INNATE PHARMA AU 1ER OCTOBRE 20…
|
French | 176.1 KB | ||
| 2020-10-13 07:00 |
Number of Shares and Voting Rights of Innate Pharma as of October 1, 2020
|
English | 130.2 KB | ||
| 2020-09-08 07:00 |
Innate Pharma présente ses résultats financiers et l'avancée de son portefeuill…
|
French | 787.1 KB | ||
| 2020-09-08 07:00 |
Innate Pharma reports first half 2020 financial results and business update
|
English | 742.7 KB | ||
| 2020-09-04 07:00 |
Prochains rendez-vous investisseurs
|
French | 132.8 KB | ||
| 2020-09-04 07:00 |
Upcoming investor conferences
|
English | 157.5 KB |
Automate Your Workflow. Get a real-time feed of all Innate Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Innate Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Innate Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-10 | N/A | Other | Buy | 6,000 | N/A |
| 2024-01-02 | N/A | Other | Buy | 20,000 | N/A |
Peer Companies
